Drug · DIN 02352303
VOTRIENT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 7, 2016; first marketed August 13, 2010.
- Drug Identification Number (DIN)
- 02352303
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Pazopanib L01EX03
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PAZOPANIB (PAZOPANIB HYDROCHLORIDE) | 200 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 30, 2015: NOC 17146New Drug Submission (NDS) · Transfer of Drug Identification Number(s)
- May 27, 2010: NOC 11446New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “votrient”. A notice may cover another product or only some lots: read it to see what it covers.
- Votrient: The dissolution is out of specification in the affected lotNovember 16, 2023 · Drugs · Product quality · Type II
- VOTRIENT (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring - For Health ProfessionalsAugust 9, 2013 · Drugs · Product safety
- VOTRIENT (pazopanib hydrochloride) - Important Change to Frequency of Liver Test Monitoring - For the PublicAugust 9, 2013 · Drugs · Product safety
Other DINs named VOTRIENT
- DIN 02352311 · Cancelled Pre Market